Current research of Zevalin and Bexxar in the field of radioimmunotherapy
- VernacularTitle:Zevalin和Bexxar在放射免疫治疗中的研究进展
- Author:
Zhao LIU
;
Junmin LI
- Publication Type:Journal Article
- Keywords:
non-Hodgkin's lymphoma;
radioimmunotherapy;
radioisotope;
CD20
- From:
Fudan University Journal of Medical Sciences
2009;36(6):786-788
- CountryChina
- Language:Chinese
-
Abstract:
Radioimmunotherapy using monoclonal antibodies incorporated with radionuclide has been showed to be an effective agent for refractory non-Hodgkin's lymphoma (NHL). Many anti-CD20 antibodies labeled with radionuclide, such as 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab tiuxetan (Bexxar), have been reported to be effective for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed NHL. This review summarizes the current advance in clinical trials and studies of Zevalin and Bexxar for the treatment of NHL patients.
